| Primary |
| Pneumonia |
14.8% |
| Sepsis |
14.8% |
| Product Used For Unknown Indication |
11.2% |
| Cystic Fibrosis |
7.8% |
| Infection |
6.4% |
| Febrile Neutropenia |
5.6% |
| Hypertension |
4.4% |
| Electrolyte Substitution Therapy |
3.9% |
| Cellulitis |
3.5% |
| Pseudomonas Infection |
3.5% |
| Pyrexia |
3.5% |
| Adult T-cell Lymphoma/leukaemia |
2.9% |
| Meningitis Bacterial |
2.9% |
| Antibiotic Therapy |
2.5% |
| Pneumonia Aspiration |
2.4% |
| Prophylaxis |
2.2% |
| Gastric Ulcer |
2.1% |
| Pain |
2.0% |
| Constipation |
1.9% |
| Urinary Tract Infection |
1.9% |
|
| Hepatic Function Abnormal |
13.6% |
| Interstitial Lung Disease |
8.7% |
| Thrombocytopenia |
7.2% |
| Pancytopenia |
6.6% |
| Anaphylactic Reaction |
5.1% |
| Platelet Count Decreased |
5.1% |
| Renal Impairment |
4.8% |
| Sepsis |
4.8% |
| Liver Disorder |
4.5% |
| Toxic Epidermal Necrolysis |
4.5% |
| Drug Eruption |
4.2% |
| Drug Interaction |
4.2% |
| Tubulointerstitial Nephritis |
4.2% |
| Septic Shock |
3.9% |
| Death |
3.6% |
| Rash |
3.6% |
| Anaphylactic Shock |
3.0% |
| Drug Ineffective |
2.7% |
| Hyperkalaemia |
2.7% |
| Stevens-johnson Syndrome |
2.7% |
|
| Secondary |
| Product Used For Unknown Indication |
24.8% |
| Sepsis |
6.8% |
| Pneumonia |
6.6% |
| Infection |
6.5% |
| Pancreatic Carcinoma Metastatic |
6.5% |
| Drug Use For Unknown Indication |
6.1% |
| Pseudomonas Infection |
5.2% |
| Pyrexia |
4.5% |
| Prophylaxis |
3.8% |
| Neutropenic Sepsis |
3.6% |
| Antibiotic Prophylaxis |
3.2% |
| Adult T-cell Lymphoma/leukaemia |
3.2% |
| Febrile Neutropenia |
3.1% |
| Mycobacterium Abscessus Infection |
3.0% |
| Cellulitis |
2.7% |
| Acute Myeloid Leukaemia |
2.6% |
| Hypertension |
2.1% |
| Device Related Infection |
1.9% |
| Osteomyelitis |
1.9% |
| Meningitis |
1.8% |
|
| Thrombocytopenia |
18.5% |
| Toxic Epidermal Necrolysis |
10.2% |
| Platelet Count Decreased |
7.1% |
| Stevens-johnson Syndrome |
6.8% |
| Pyrexia |
5.8% |
| Tachycardia |
4.8% |
| Interstitial Lung Disease |
4.6% |
| Bradycardia |
3.9% |
| Death |
3.7% |
| Renal Failure |
3.7% |
| White Blood Cell Count Decreased |
3.7% |
| Pneumonia |
3.5% |
| Septic Shock |
3.3% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
3.1% |
| Hepatic Function Abnormal |
3.1% |
| Drug Eruption |
2.9% |
| Renal Failure Acute |
2.9% |
| Renal Impairment |
2.9% |
| Sepsis |
2.7% |
| Staphylococcal Infection |
2.7% |
|
| Concomitant |
| Product Used For Unknown Indication |
33.9% |
| Drug Use For Unknown Indication |
10.2% |
| Prophylaxis |
10.1% |
| Infection Prophylaxis |
6.0% |
| Acute Myeloid Leukaemia |
5.2% |
| Pneumonia |
3.8% |
| Infection |
3.5% |
| Acute Lymphocytic Leukaemia |
3.2% |
| Bone Marrow Conditioning Regimen |
3.0% |
| Prophylaxis Against Graft Versus Host Disease |
2.8% |
| Pyrexia |
2.4% |
| Sepsis |
2.2% |
| Hypertension |
2.2% |
| Antifungal Prophylaxis |
2.0% |
| Premedication |
1.9% |
| Pain |
1.8% |
| Constipation |
1.5% |
| Immunosuppression |
1.5% |
| Nausea |
1.3% |
| Febrile Neutropenia |
1.3% |
|
| Sepsis |
12.8% |
| Pneumonia |
8.8% |
| Respiratory Failure |
7.0% |
| Septic Shock |
7.0% |
| White Blood Cell Count Decreased |
7.0% |
| Pyrexia |
6.5% |
| Thrombocytopenia |
6.2% |
| Renal Failure Acute |
5.8% |
| Vomiting |
5.3% |
| Multi-organ Failure |
5.0% |
| Renal Failure |
4.3% |
| Death |
3.7% |
| Pancytopenia |
3.3% |
| Renal Impairment |
2.9% |
| Neutropenia |
2.7% |
| Platelet Count Decreased |
2.6% |
| Shock |
2.5% |
| Febrile Neutropenia |
2.4% |
| Infection |
2.2% |
| Staphylococcal Infection |
2.2% |
|
| Interacting |
| Product Used For Unknown Indication |
23.7% |
| Periorbital Cellulitis |
13.0% |
| Status Epilepticus |
10.7% |
| Chest Pain |
6.5% |
| Drug Use For Unknown Indication |
6.5% |
| Infection |
5.8% |
| Pneumonia |
4.9% |
| Pulmonary Embolism |
3.6% |
| Epilepsy |
3.2% |
| Grand Mal Convulsion |
3.2% |
| Chalazion |
2.9% |
| Convulsion |
2.9% |
| Antibiotic Therapy |
2.6% |
| Escherichia Infection |
1.9% |
| Acute Promyelocytic Leukaemia |
1.6% |
| Myoclonic Epilepsy |
1.6% |
| Pain |
1.6% |
| Constipation |
1.3% |
| Partial Seizures |
1.3% |
| Bacterial Infection |
1.0% |
|
| Drug Interaction |
22.0% |
| Electroencephalogram Abnormal |
18.6% |
| Pyrexia |
13.6% |
| Myositis |
5.1% |
| Convulsion |
3.4% |
| Drug Level Below Therapeutic |
3.4% |
| Drug Level Decreased |
3.4% |
| Grand Mal Convulsion |
3.4% |
| Intraocular Pressure Increased |
3.4% |
| Renal Impairment |
3.4% |
| Simple Partial Seizures |
3.4% |
| Tubulointerstitial Nephritis |
3.4% |
| Hepatic Enzyme Increased |
1.7% |
| International Normalised Ratio Increased |
1.7% |
| Leukopenia |
1.7% |
| Nausea |
1.7% |
| Pancytopenia |
1.7% |
| Platelet Count Decreased |
1.7% |
| Red Blood Cell Count Decreased |
1.7% |
| Respiratory Failure |
1.7% |
|
